fasudil has been researched along with Insulin Resistance in 4 studies
fasudil: intracellular calcium antagonist; structure in first source
fasudil : An isoquinoline substituted by a (1,4-diazepan-1-yl)sulfonyl group at position 5. It is a Rho-kinase inhibitor and its hydrochloride hydrate form is approved for the treatment of cerebral vasospasm and cerebral ischemia.
Insulin Resistance: Diminished effectiveness of INSULIN in lowering blood sugar levels: requiring the use of 200 units or more of insulin per day to prevent HYPERGLYCEMIA or KETOSIS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of this study was to evaluate the effects of fasudil on insulin resistance (IR) in HTR-8/SVneo cells." | 8.02 | Fasudil alleviated insulin resistance through promotion of proliferation, attenuation of cell apoptosis and inflammation and regulation of RhoA/Rho kinase/insulin/nuclear factor-κB signalling pathway in HTR-8/SVneo cells. ( Bai, Y; Du, Q; Du, R; Li, L; Li, P; Tang, L; Zhang, L; Zhang, W, 2021) |
| "The aim of this study was to evaluate the effects of fasudil on insulin resistance (IR) in HTR-8/SVneo cells." | 4.02 | Fasudil alleviated insulin resistance through promotion of proliferation, attenuation of cell apoptosis and inflammation and regulation of RhoA/Rho kinase/insulin/nuclear factor-κB signalling pathway in HTR-8/SVneo cells. ( Bai, Y; Du, Q; Du, R; Li, L; Li, P; Tang, L; Zhang, L; Zhang, W, 2021) |
| " Treatment with the Rho-kinase inhibitor fasudil attenuated weight gain and insulin resistance in mice on a HFD." | 3.77 | Rho and Rho-kinase activity in adipocytes contributes to a vicious cycle in obesity that may involve mechanical stretch. ( Fujimura, K; Hara, Y; Hasegawa, K; Hayashi, K; Homma, K; Hosoya, K; Itoh, H; Minakuchi, H; Nakayama, K; Saito, M; Tanabe, Y; Tatematsu, S; Tokuyama, H; Wakino, S; Washida, N; Yoshioka, K, 2011) |
| "Non-alcoholic fatty liver disease (NAFLD) is linked to type 2 diabetes mellitus (T2DM), obesity, and insulin resistance." | 1.72 | Rho-kinase inhibition ameliorates non-alcoholic fatty liver disease in type 2 diabetic rats. ( Abdullah, DM; Al-Zahaby, SA; Ebrahim, HA; Elkattawy, HA; Elsherbini, DM; Hassan, AE; Noser, Y, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 2 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Elkattawy, HA | 1 |
| Elsherbini, DM | 1 |
| Ebrahim, HA | 1 |
| Abdullah, DM | 1 |
| Al-Zahaby, SA | 1 |
| Noser, Y | 1 |
| Hassan, AE | 1 |
| Bai, Y | 1 |
| Du, Q | 1 |
| Zhang, L | 1 |
| Li, L | 2 |
| Tang, L | 1 |
| Zhang, W | 1 |
| Du, R | 1 |
| Li, P | 1 |
| Hara, Y | 1 |
| Wakino, S | 2 |
| Tanabe, Y | 1 |
| Saito, M | 1 |
| Tokuyama, H | 1 |
| Washida, N | 1 |
| Tatematsu, S | 2 |
| Yoshioka, K | 2 |
| Homma, K | 2 |
| Hasegawa, K | 2 |
| Minakuchi, H | 1 |
| Fujimura, K | 1 |
| Hosoya, K | 1 |
| Hayashi, K | 2 |
| Nakayama, K | 1 |
| Itoh, H | 1 |
| Kanda, T | 1 |
| Takamatsu, I | 1 |
| Sugano, N | 1 |
| Saruta, T | 1 |
4 other studies available for fasudil and Insulin Resistance
| Article | Year |
|---|---|
Rho-kinase inhibition ameliorates non-alcoholic fatty liver disease in type 2 diabetic rats.
Topics: Animals; Body Weight; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diet, High-Fat; In | 2022 |
Fasudil alleviated insulin resistance through promotion of proliferation, attenuation of cell apoptosis and inflammation and regulation of RhoA/Rho kinase/insulin/nuclear factor-κB signalling pathway in HTR-8/SVneo cells.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Apoptosis; Caspase 3; Cell Survival; Cells, Cultured; | 2021 |
Rho and Rho-kinase activity in adipocytes contributes to a vicious cycle in obesity that may involve mechanical stretch.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Adipocytes; Animals; Diet, Fat-Restricted; Insulin Re | 2011 |
Rho-kinase as a molecular target for insulin resistance and hypertension.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Acetylcholine; Animals; Arterioles; Cell Line; Glucos | 2006 |